Abeomics specializes in the development and production of a wide range of biological research tools, particularly focusing on antibodies, proteins, and cell lines. Their offerings include recombinant biosimilar antibodies such as Trastuzumab and Efalizumab, as well as SARS-CoV-2 research tools, which encompass neutralizing antibodies, detection kits, and drug screening kits. The company also provides custom services aimed at accelerating research, including drug discovery screening, stable cell line development, and custom antibody development. Their product catalog features various stable cell lines, including those expressing TLR proteins and GFP, which are essential for functional assays and other applications in life sciences.

In addition to their antibody and cell line offerings, Abeomics has advanced capabilities in protein production, utilizing various expression systems such as baculovirus, bacterial, and mammalian cell lines. This versatility allows them to cater to the specific needs of clients in academia, biotechnology, and pharmaceutical laboratories. Their facility in San Diego is equipped for large-scale purification and biologic protein production, ensuring high-quality outputs for drug development and research applications. The company emphasizes collaboration with clients, providing detailed project reports and online tracking to ensure transparency and efficiency throughout the production process.

United States

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abeomics

Company Details